# EDGAR Filing Document

**Accession Number:** 0001540171
**File Stem:** 0001193125-26-197739
**Filing Date:** 2026-4
**Character Count:** 37710
**Document Hash:** a88b2dbc020ebe54e34e61cb67b17159
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-197739.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0001193125-26-197739

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260430

**DATE AS OF CHANGE**: 20260430

**EFFECTIVENESS DATE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Avalyn Pharma Inc.
- **CENTRAL INDEX KEY:** 0001540171
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 452463191
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295462
- **FILM NUMBER:** 26926819

**BUSINESS ADDRESS:**
- **STREET 1:** 105 W FIRST ST.
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02127
- **BUSINESS PHONE:** (206) 707-0340

**MAIL ADDRESS:**
- **STREET 1:** 105 W FIRST ST.
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02127

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Genoa Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20120120

**As filed with the Securities and Exchange Commission on April 30, 2026** 

**Registration No. 333-** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM S-8** 

**REGISTRATION STATEMENT** 

***Under*** 

***The Securities Act of 1933*** 

------

**Avalyn Pharma Inc.** 

**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **45-2463191** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

**Avalyn Pharma Inc.** 

**105 W First Street**

**Boston, Massachusetts 02127** 

**(206) 707-0340** 

**(Address, including zip code and telephone number, including area code, of Registrant's principal executive offices)** 

**Avalyn Pharma Inc. 2012 Equity Incentive Plan**

**Avalyn Pharma Inc. 2022 Equity Incentive Plan** 

**Avalyn Pharma Inc. 2026 Equity Incentive Plan**

**Avalyn Pharma Inc. 2026 Employee Stock Purchase Plan** 

**(Full title of the plans)** 

**Lyn Baranowski**

**Chief Executive Officer** 

**Avalyn Pharma Inc.** 

**105 W First Street**

**Boston, Massachusetts 02127** 

**(206) 707-0340**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

------

***Copies to:*** 

**Mitchell S. Bloom** 

**Stephanie Richards <br>Kristen M. McCarthy**

**Goodwin Procter LLP** 

**100 Northern Avenue** 

**Boston, Massachusetts 02210** 

**(617) 570-1000** 

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**Part I** 

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS** 

**Item 1. Plan Information.** 

The documents containing the information specified in this Item 1 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the "Securities Act"). In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the "Commission") and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement on Form S-8 (this "Registration Statement") or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

**Item 2. Registrant Information and Employee Plan Annual Information.** 

The documents containing the information specified in this Item 2 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

**Part II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3. Incorporation of Documents by Reference.** 

The registrant hereby incorporates by reference into this Registration Statement the following documents filed with the Commission:

(a)The [<u>Amendment No. 1</u>](https://www.sec.gov/Archives/edgar/data/1540171/000119312526173632/ck0001540171-20260423.htm) to the registrant's Registration Statement on Form S-1 filed with the Commission on April 23, 2026 (File No. 333-294932), which contains the registrant's audited financial statements for the latest fiscal year for which such statements have been filed; and

(b)The description of the registrant's common stock, par value $0.001 per share (the "Common Stock") contained in the registrant's Registration Statement on [<u>Form 8-A</u>](https://www.sec.gov/Archives/edgar/data/1540171/000119312526182253/avalyn_pharma_-_form_8-a.htm) (File No. 001-43251), filed by the registrant with the Commission under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), on April 27, 2026, including any amendments or reports filed for the purpose of updating such description.

All documents that the registrant subsequently files pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Under no circumstances will any information filed under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

------

**Item 4. Description of Securities.** 

Not applicable.

**Item 5. Interests of Named Experts and Counsel.** 

Not applicable.

**Item 6. Indemnification of Directors and Officers.** 

Section 145 of the Delaware General Corporation Law (the "DGCL") authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys' fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys' fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.

The registrant has adopted provisions in its Amended and Restated Certificate of Incorporation ("Charter") and Amended and Restated Bylaws ("Bylaws"), each to be effective upon the closing of the registrant's initial public offering, that limit or eliminate the personal liability of the registrant's directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, the registrant's directors and officers will not be personally liable to the registrant or its stockholders for monetary damages or a breach of fiduciary duty in their capacities and directors and officers, except for liability:

• for any breach of a director or officer's duty of loyalty to the registrant or its stockholders;

• for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;

• for any transaction from which the director or officer derived an improper personal benefit;

• arising under Section 174 of the DGCL for directors; and

• arising from any claim brought or in the right of the registrant for officers.

These limitations of liability do not alter director and officer liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

In addition, the Bylaws provide that:

• the registrant will indemnify its directors, officers and, in the discretion of its board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and

• the registrant will advance reasonable expenses, including attorneys' fees, to its directors and, at the discretion of its board of directors, to officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of the registrant, subject to limited exceptions.

The registrant has entered into indemnification agreements with each of its directors and officers. These agreements provide that the registrant will indemnify each of its directors, officers and, at times, their affiliates to the fullest extent permitted by the DGCL. The registrant will advance expenses, including attorneys' fees (but excluding judgments, fines and settlement amounts), to each indemnified director, officer or affiliate in connection with any proceeding in which indemnification is available and the registrant will indemnify its directors and officers for any action or proceeding arising out of that person's services as a director or officer brought on behalf of the registrant or in furtherance of the registrant's rights. Additionally, certain of the registrant's directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third

------

parties, which indemnification relates to and might apply to the same proceedings arising out of such director's or officer's services as a director referenced herein. Nonetheless, the registrant has agreed in the indemnification agreements that its obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.

The registrant also maintains general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act.

**Item 7. Exemption from Registration Claimed.** 

Not applicable.

------

**Item 8. Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Exhibit table** |
| 4.1 | [<u>Form of Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.3 to the registrant's Registration Statement on Form S-1, as amended (File No. 333-294932)).</u>](https://www.sec.gov/Archives/edgar/data/1540171/000119312526173632/ck0001540171-ex3_3.htm) |
| 4.2 | [<u>Form of Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.5 to the registrant's Registration Statement on Form S-1, as amended (File No. 333-294932)).</u>](https://www.sec.gov/Archives/edgar/data/1540171/000119312526173632/ck0001540171-ex3_5.htm) |
| 4.3 | [<u>Amended and Restated Investors' Rights Agreement among the Registrant and certain of its stockholders, dated as of April 25, 2025 (Incorporated by reference to Exhibit 4.2 to the registrant's Registration Statement on Form S-1, as amended (File No. 333-294932)).</u>](https://www.sec.gov/Archives/edgar/data/1540171/000119312526147573/ck0001540171-ex4_2.htm) |
| 4.4 | [<u>Specimen Common Stock Certificate (Incorporated by reference to Exhibit 4.1 to the registrant's Registration Statement on Form S-1, as amended (File No. 333-294932)).</u>](https://www.sec.gov/Archives/edgar/data/1540171/000119312526147573/ck0001540171-ex4_1.htm) |
| 5.1\* | [<u>Opinion of Goodwin Procter LLP.</u>](ck0001540171-ex5_1.htm) |
| 23.1\* | [<u>Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.</u>](ck0001540171-ex23_1.htm) |
| 23.2\* | [<u>Consent of Goodwin Procter LLP (included in Exhibit 5.1).</u>](ck0001540171-ex5_1.htm) |
| 24.1\* | [<u>Power of Attorney (included on signature page).</u>](#sig) |
| 99.1 | [<u>2012 Equity Incentive Plan, as amended, and form of award agreements thereunder (Incorporated by reference to Exhibit 10.1 to the registrant's Registration Statement on Form S-1, as amended (File No. 333-294932)).</u>](https://www.sec.gov/Archives/edgar/data/1540171/000119312526147573/ck0001540171-ex10_1.htm) |
| 99.2 | [<u>2022 Equity Incentive Plan, as amended, and form of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the registrant's Registration Statement on Form S-1, as amended (File No. 333-294932)).</u>](https://www.sec.gov/Archives/edgar/data/1540171/000119312526147573/ck0001540171-ex10_2.htm) |
| 99.3 | [<u>2026 Equity Incentive Plan and form of award agreements thereunder (Incorporated by reference to Exhibit 10.3 to the registrant's Registration Statement on Form S-1, as amended (File No. 333-294932))</u>](https://www.sec.gov/Archives/edgar/data/1540171/000119312526173632/ck0001540171-ex10_3.htm)<u>.</u> |
| 99.4 | [<u>2026 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.4 to the registrant's Registration Statement on Form S-1, as amended (File No. 333-294932)).</u>](https://www.sec.gov/Archives/edgar/data/1540171/000119312526173632/ck0001540171-ex10_4.htm) |
| 107\* | [<u>Filing Fee table.</u>](ck0001540171-exfiling_fees.htm) |
| \* | Filed herewith.  |

---

------

**Item 9. Undertakings.** 

(a) The registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act.

(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the Registration Statement.

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the registration statement.

*Provided, however*, that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Boston, Massachusetts, on this 30th day of April, 2026.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**Avalyn Pharma Inc.** | &nbsp;&nbsp;&nbsp;**Avalyn Pharma Inc.** |
| By: | /s/ Lyn Baranowski |
|  | &nbsp;&nbsp;&nbsp;Name: Lyn Baranowski |
|  | &nbsp;&nbsp;&nbsp;Title: Chief Executive Officer |

---

**POWER OF ATTORNEY AND SIGNATURES** 

KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Lyn Baranowski and Douglas Carlson, as such person's true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **NAME** | **TITLE** | **DATE** |
| /s/ Lyn Baranowski<br>Lyn Baranowski | &nbsp;&nbsp;&nbsp;Chief Executive Officer and Director<br>(Principal Executive Officer) | April 30, 2026 |
| /s/ Douglas Carlson<br>Douglas Carlson | &nbsp;&nbsp;&nbsp;Chief Financial Officer<br>(Principal Financial Officer and Principal Accounting Officer) | April 30, 2026 |
| /s/ Heather Turner<br>Heather Turner | &nbsp;&nbsp;&nbsp;Director | April 30, 2026 |
| /s/ Jill Carroll<br>Jill Carroll | &nbsp;&nbsp;&nbsp;Director | April 30, 2026 |
| /s/ David Friedman, M.D.<br>David Friedman, M.D. | &nbsp;&nbsp;&nbsp;Director | April 30, 2026 |
| /s/ Kate Haviland<br>Kate Haviland | &nbsp;&nbsp;&nbsp;Director | April 30, 2026 |
| /s/ Erin Lavelle<br>Erin Lavelle | &nbsp;&nbsp;&nbsp;Director | April 30, 2026 |
| /s/ Jon Congleton<br>Jon Congleton | &nbsp;&nbsp;&nbsp;Director | April 30, 2026 |

---

------

## Exhibit 5.1

![img154328349_0.jpg](img154328349_0.jpg)

**Exhibit 5.1**

Goodwin Procter LLP100 Northern Avenue<br>Boston, MA 02210 goodwinlaw.com<br>+1 617 570 1000

April 30, 2026

Avalyn Pharma Inc.

105 W First Street

Boston, MA 02127

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as your counsel in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 16,666,667 shares (the "Shares") of voting common stock, $0.001 par value per share ("Common Stock"), of Avalyn Pharma Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Company's 2012 Equity Incentive Plan, as amended, 2022 Equity Incentive Plan, as amended, 2026 Stock Option and Incentive Plan, and 2026 Employee Stock Purchase Plan (collectively, the "Plans").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

For purposes of the opinion set forth below, we have assumed that, at the time Shares are issued, the total number of then unissued Shares, when added to the number of shares of Common Stock issued, subscribed for, or otherwise committed to be issued, does not exceed the number of shares of Common Stock authorized by the Company's certificate of incorporation.

The opinion set forth below is limited to the Delaware General Corporation Law.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered against payment therefor in accordance with the terms of the Plans, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 *Business Lawyer* 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

------

Avalyn Pharma Inc.

April 30, 2026

---

| |
|:---|
| Very truly yours, |
| /s/ Goodwin Procter LLP |
| GOODWIN PROCTER LLP |

---

------

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 18, 2026 (April 23, 2026, as to the effects of the reverse stock split and stock option grants disclosed in Note 16) relating to the financial statements of Avalyn Pharma Inc., appearing in registration statement No. 333-294932 on Form S-1 of Avalyn Pharma Inc. for the year ended December 31, 2025.

/s/ Deloitte & Touche LLP

Boston, Massachusetts

April 30, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Avalyn Pharma Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, par value $0.001 per share | Other | 273814 | $5.32 | $1456690.48 | 0.0001381 | $201.17 |
| 2 | Equity | Common Stock, par value $0.001 per share | Other | 4117038 | $5.19 | $21367427.22 | 0.0001381 | $2950.84 |
| 3 | Equity | Common Stock, par value $0.001 per share | Other | 4160000 | $18.00 | $74880000.00 | 0.0001381 | $10340.93 |
| 4 | Equity | Common Stock, par value $0.001 per share | Other | 370000 | $15.30 | $5661000.00 | 0.0001381 | $781.78 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $103365117.70  |  | $14274.72  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $14274.72  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 ("Registration Statement") shall also cover any additional shares of common stock, par value $0.001 per share (the "Common Stock") of Avalyn Pharma Inc. (the "Company"), which become issuable under the Company's 2012 Equity Incentive Plan (the "2012 Plan"), 2022 Equity Incentive Plan (the "2022 Plan"), 2026 Stock Option and Incentive Plan, as amended (the "2026 Plan") and 2026 Employee Stock Purchase Plan (the "ESPP") by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of Common Stock. Pursuant to Rule 416(c) under the Securities Act, this Registration Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein. (2) Represents 273,814 shares of Common Stock issuable upon the exercise of outstanding equity awards under the 2012 Plan as of the date of this Registration Statement. No further grants will be made under the 2012 Plan. To the extent outstanding options granted under the 2012 Plan are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2012 Plan, the number of shares underlying such awards will be available for future grant under the 2026 Plan. (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on $5.32, the weighted average exercise price (rounded to the nearest cent) of the outstanding option awards under the 2012 Plan as of the date of this Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 ("Registration Statement") shall also cover any additional shares of common stock, par value $0.001 per share (the "Common Stock") of Avalyn Pharma Inc. (the "Company"), which become issuable under the Company's 2012 Equity Incentive Plan (the "2012 Plan"), 2022 Equity Incentive Plan (the "2022 Plan"), 2026 Stock Option and Incentive Plan, as amended (the "2026 Plan") and 2026 Employee Stock Purchase Plan (the "ESPP") by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of Common Stock. Pursuant to Rule 416(c) under the Securities Act, this Registration Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein. (4) Represents 4,117,038 shares of Common Stock issuable upon the exercise of outstanding equity awards under the 2022 Plan as of the date of this Registration Statement. No further grants will be made under the 2022 Plan. To the extent outstanding options granted under the 2022 Plan are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2022 Plan, the number of shares underlying such awards will be available for future grant under the 2026 Plan. (5) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on $5.19, the weighted average exercise price (rounded to the nearest cent) of the outstanding option awards under the 2022 Plan as of the date of this Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>3</sup> (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 ("Registration Statement") shall also cover any additional shares of common stock, par value $0.001 per share (the "Common Stock") of Avalyn Pharma Inc. (the "Company"), which become issuable under the Company's 2012 Equity Incentive Plan (the "2012 Plan"), 2022 Equity Incentive Plan (the "2022 Plan"), 2026 Stock Option and Incentive Plan, as amended (the "2026 Plan") and 2026 Employee Stock Purchase Plan (the "ESPP") by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of Common Stock. Pursuant to Rule 416(c) under the Securities Act, this Registration Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein. (6) Represents 4,160,000 shares of Common Stock reserved for issuance under the 2026 Plan. If awards outstanding under the 2012 Plan and 2022 Plan, as of the date of this Registration Statement, and under the 2026 Plan, are cancelled, forfeited or otherwise terminated without being exercised, the number of shares underlying such awards will be available for future grant under the 2026 Plan. The 2026 Plan provides that an additional number of shares will automatically be added to the shares authorized for issuance under the 2026 Plan on January 1 of each year, commencing on January 1, 2027. The number of shares added each year will be equal to the lesser of: (i) 5% of the outstanding shares and pre-funded warrants on the immediately preceding December 31, or (ii) such lesser amount as determined by the Administrator (as such term is defined in the 2026 Plan). (7) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) and 457(c) of the Securities Act, and based on $18.00, the initial public offering price of the Company's Common Stock set forth in the Company's final prospectus dated April 29, 2026 relating to its initial public offering (the "IPO Price").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>4</sup> (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 ("Registration Statement") shall also cover any additional shares of common stock, par value $0.001 per share (the "Common Stock") of Avalyn Pharma Inc. (the "Company"), which become issuable under the Company's 2012 Equity Incentive Plan (the "2012 Plan"), 2022 Equity Incentive Plan (the "2022 Plan"), 2026 Stock Option and Incentive Plan, as amended (the "2026 Plan") and 2026 Employee Stock Purchase Plan (the "ESPP") by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of Common Stock. Pursuant to Rule 416(c) under the Securities Act, this Registration Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein. (8) Represents 370,000 shares of Common Stock reserved for future issuance under the ESPP. The ESPP provides that an additional number of shares will automatically be added to the shares authorized for issuance under the ESPP on January 1, 2027, and each January 1 thereafter through January 1, 2036. The number of shares added each year will be equal to the lesser of: (i) 1% of the outstanding shares and pre-funded warrants on the immediately preceding December 31, (ii) 740,000 shares of common stock, or (iii) such lesser number of shares of common stock as determined by the administrator of the ESPP. (9) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and 457(c) of the Securities Act. The proposed maximum offering price per share and proposed maximum aggregate offering price are calculated on the basis of the IPO Price, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the ESPP.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---